Navigation Links
Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine

Antigenics Pharmaceuticals is to start its Phase III cancer vaccine trial against Melanoma which is a type of skin cancer. Oncophage is the new skin cancer vaccine developed by Antigenics.// The vaccine trial of Oncophage which was conducted in 322 patients failed to meet the required statistically significance results compared to prolongation in survival and the vaccine was not shown to have any better results compared to other cancer treatments.

But, earlier studies with Oncophage showed a group of patients with the least-advanced severity of melanoma in the trial lived 20.9 months on Oncophage compared to 12.8 months for those patients taking standard drugs, the company said. The difference had not yet reached statistical significance and the trial is continuing.

Antigenics is to start a Phase III study next year to test its vaccine on a more responsive group, patients with Stage IV M1a patients. Though, the trial is to cost the company more than $12 million the scientists of the company are confident over the results.

Needham & Co. analyst Mark Monane in a research note called the data "encouraging" but only "hypothesis-generating rather than hypothesis-confirming, that we believe that any intensive reading into the data at this stage may be premature."
'"/>




Page: 1

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
4. Top Pharmaceuticals Influence Doctors Prescriptions
5. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
6. Personalized Medicine and Innovative Pharmaceuticals
7. Pravastatin Launched by Watson Pharmaceuticals
8. Tata Industries picks up stake in Indigene Pharmaceuticals
9. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
10. OPPI Opposes Draft National Pharmaceuticals Policy
11. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2020)... , ... February 26, 2020 , ... ... editing platforms company Transposagen (now a Hera BioLabs company) which is best known ... CRISPR and dual-guided CRISPR nickase systems as it is truly dimeric and demonstrates ...
(Date:2/23/2020)... ... February 22, 2020 , ... ... Laurence Fishburne ( https://www.imdb.com/name/nm0000401/mediaindex ) is the host of the informational program “Behind ... of topics affecting people across the country. A soon to be aired episode ...
(Date:2/21/2020)... ... February 21, 2020 , ... Used for years as a ... traction as a viable replacement for invasive cosmetic surgery, such as breast augmentation. ... remain the market leader for the expected robust growth of autologous fat grafting ...
(Date:2/20/2020)... ... ... R3 Stem Cell, the nation's leader in regenerative therapies and provider training, ... procedures on military veterans in 2019. The veterans traveled from all over the ... Cell Training Course for doctors , providers of all kinds learn how to perform ...
(Date:2/19/2020)... ... February 19, 2020 , ... The American College of Lifestyle ... Lifestyle Medicine Residency Curriculum (LMRC). The curriculum is the first comprehensive, applicable and ... Driven by resident involvement, the curriculum has included residents in every aspect of ...
Breaking Medicine News(10 mins):
(Date:2/20/2020)... ... ... NJ Top Docs practice, The Rubino OB/GYN Group hosted a ribbon-cutting ceremony ... 16 at 12PM. The Rubino OB/GYN Group founder, Dr. Robert Rubino, was joined ... public and media were also in attendance. , The office space at 27 Mountain ...
(Date:2/20/2020)... ... February 20, 2020 , ... NeoTract, ... in the field of urology, today announced that Jayant Uberoi, MD, Chesapeake Urology ... designation recognizes that Dr. Uberoi has achieved a high level of training and ...
(Date:2/19/2020)... (PRWEB) , ... February 19, 2020 , ... A new ... presence of oxygen-deprived clusters throughout the damaged site of a compressed spinal cord. It ... of a viral vector to target the oxygen-deprived sites enhances the injured spinal cord’s ...
Breaking Medicine Technology: